Clinical Trial

A Study of SPY003-207 in Healthy Volunteers

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase 1, randomized, double-blind, placebo-controlled, single dose, first in human safety, tolerability, and pharmacokinetic study of SPY003-207 in healthy participants.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-03-12; most recent amendment 2026-03-18.
Status change: Recruiting → Active, Not Recruiting 2026-03-18
Trial Details
NCT Number NCT06873724
Lead Sponsor Spyre Therapeutics, Inc.
Collaborators: Altasciences Company Inc.
Conditions Healthy
Enrollment 59 participants
Start Date 2025-03-10
Primary Completion 2026-11-18 (estimated)
Study Completion 2026-11-18 (estimated)
Updated on ClinicalTrials.gov 2026-03-20